Glaxosmithkline Pharmaceuticals Ltd Share Price Today - Glaxosmithkline Pharmaceuticals Ltd Stock Price Live NSE/BSE

Glaxosmithkline Pharmaceuticals Ltd

NSE: GLAXO BSE: 500660

₹2384.80

(0.34%)

Mon, 30 Mar 2026, 02:00 am

MTF 5xInvest in Glaxosmithkline Pharmaceuticals Ltd with 5x Leverage Buy with MTF

Market Cap403.34B

PE Ratio39.57

Dividend1.76

Health Technology

Pharmaceuticals: Major

24.5K

Glaxosmithkline Pharmaceuticals Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
38272.21
Net Profit
927.58
P/B
24.98
Sector P/E
31.93
P/E
52.54
EV/EBITDA
35.66
Debt/Equity (Industry)
0.09
Interest Cover (Industry)
40.26
ROCE (Industry)
22.97
RONW (Industry)
18.34
ROE
49.75
ROCE
59.29
Debt/Equity
0.01
EPS (TTM)
59.37
Dividend Yield
2.39
Book Value
100.80
Interest Cover
962.74

Analysis

all

Pros

Dividends per share have increased over the past 10 years.
Dividends after 3 years are expected to be covered by earnings (1.5x coverage).
GlaxoSmithKline Pharmaceuticals's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
GlaxoSmithKline Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
GlaxoSmithKline Pharmaceuticals's earnings growth is expected to exceed the India market average.

Cons

Dividends paid are not well covered by earnings (0.3x coverage).
Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
GlaxoSmithKline Pharmaceuticals's dividend is below the markets top 25% of dividend payers in India (3.08%).
Cash flow for GlaxoSmithKline Pharmaceuticals is expected to increase but not above the 50% threshold in 2 years time.
GlaxoSmithKline Pharmaceuticals's revenue is expected to increase but not above the 50% threshold in 2 years time.

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	75	75	75	75	75
FII	4.64	4.79	4.88	4.52	4.50
DII	7.70	7.75	7.70	7.79	7.30
Public	12.66	12.45	12.41	12.69	13.19
Government	0.00	0.00	0.00	0.00	0.00

Technical Analysis

RSI

31.08

MACD

-60.20

50 DMA

2464.98

200 DMA

2713.04

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	3299.90	2922.20	2746.90	2544.50	2369.20	2166.80	1789.10
Fibonacci	2922.20	2777.92	2688.78	2544.50	2400.22	2311.08	2166.80
Camarilla	2675.47	2640.84	2606.22	2544.50	2536.98	2502.36	2467.73

Pivots Level: Classic

+755.40

3299.90

+377.70

2922.20

+202.40

2746.90

2544.50

Pivot Point

LTP: 2259.50

-175.30

2369.20

-377.70

2166.80

-755.40

1789.10

Moving Average

SMAEMA

Period

Value

10-EMA
2357.26
20-EMA
2414.22
30-EMA
2440.71
50-EMA
2466.02
100-EMA
2521.13
200-EMA
2591.80

Announcement Date	Purpose	Action	Ex Date
09 Feb 2026	board-meetings	Quarterly Results
06 Nov 2025	board-meetings	Quarterly Results, Half Yearly Results
13 May 2025	dividend	₹42.00 Dividend /Share	30 May 2025
13 May 2025	agm
30 Apr 2025	dividend	Final Dividend - Rs. - 42	30 May 2025
29 Oct 2024	dividend	₹12.00 Dividend /Share	07 Nov 2024
07 Oct 2024	dividend	Interim Dividend - Rs. - 12	07 Nov 2024
17 May 2024	dividend	₹32.00 Dividend /Share	31 May 2024
17 May 2024	agm
01 May 2024	dividend	Final Dividend - Rs. - 32	31 May 2024

Glaxosmithkline Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd

Lupin Ltd

Divis Laboratories Ltd

Glaxosmithkline Pharmaceuticals Ltd About

GlaxoSmithKline Pharmaceuticals is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

Industry

Pharmaceuticals - Multinational

Founded

1924

Headquarters

CEO

Renu S Karnad

Employees

Contact

Website

http://www.gsk-india.com

askus@gsk.com; ajay.a.nadkarni@gsk.com

Phone

91-022-24959595

Location

GSK House, Dr Annie Besant Road Worli, Mumbai, Maharashtra, 400030

Year	History
2019	Won Brand of the Year award in acute category at 6th AWACS Awards. Won Best Sales and Operations Planning Practice in Pharma award. Recognised as Best Workplaces for Women by Great Places to Work India.
2020	Recognised as one of 100 Best Companies for Women in India by Working Mother and AVTAR. Conferred Fair Business Practices award (2019-20) by Council for Fair Business Practices. Recognised as Silver employer under India Workplace Equality Index.
2021	Recognised as one of India's Best Workplaces in Health & Wellness by Great Place to Work. Conferred CNBC TV18 India Risk Management Award in Pharma sector.
2022	Launched once-daily single inhaler-triple therapy for COPD patients. Teamed up with MS Dhoni for 6-in-1 vaccination awareness campaign.
2024	Reported strong double-digit growth and improved profitability for the quarter.

Client Name	Order Side	QTY	Avg Price	Date
T ROWE PRICE INTERNATIONAL INC	Sell	1087076	1207	18 May 2007
HSBC INVESTMENTS HONG KONG LIMITED	Buy	1047076	1207	18 May 2007
ABERDEN GLOBAL	Buy	560050	1463	30 Mar 2006
ABERDEN GLOBAL	Buy	25000	1463	30 Mar 2006
ADBERDEN INTL FUN ASIA	Sell	560050	1463	30 Mar 2006
ABERDEN INTL EMERGING	Sell	25000	1463	30 Mar 2006

Glaxosmithkline Pharmaceuticals Ltd News

GSK Pharma Receives Rs 23.21 Crore Tax Demand

GlaxoSmithKline Pharmaceuticals receives Rs 23.21 crore demand liability from ACIT for AY 2023-24. Company plans to contest the assessment order through appellate authority with no current financial impact.

24 Mar 2026

companies

GSK Pharma CFO Juby Chandy Resigns for Regional Role

GlaxoSmithKline Pharmaceuticals CFO and Whole-Time Director Juby Chandy resigned effective March 11, 2026, following appointment as Finance Head for GSK's Asia Pacific region.

16 Mar 2026

companies

GSK Pharma receives GST demand of Rs 6.93 crore

GlaxoSmithKline Pharmaceuticals receives GST demand order of Rs 6,92,76,478 from Maharashtra authorities for alleged non-payment related to export of services during April 2022 to March 2023.

07 Mar 2026

stocks

GSK Pharma Appoints New CFO & Whole-Time Director

GlaxoSmithKline Pharmaceuticals appoints Ronojit Biswas as Whole-Time Director & CFO for three years from April 1, 2026, while current CFO Juby Chandy transitions to new GSK Group role.

02 Mar 2026

stocks

GSK Pharma Faces DRI Search at Mumbai Office

GlaxoSmithKline Pharmaceuticals disclosed that the Directorate of Revenue Intelligence conducted a search at its Mumbai registered office under Customs Act provisions on February 27-28, 2026.

28 Feb 2026

stocks

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800